vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and YORK WATER CO (YORW). Click either name above to swap in a different company.
YORK WATER CO is the larger business by last-quarter revenue ($19.4M vs $18.6M, roughly 1.0× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 26.7%, a 39.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 3.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 5.1%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
The York Water Company is an investor-owned, public utility company based in York, Pennsylvania and operating throughout Pennsylvania. The company was founded in 1816 by a group of local businessmen concerned about fire protection.
SCYX vs YORW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $19.4M |
| Net Profit | $12.3M | $5.2M |
| Gross Margin | — | — |
| Operating Margin | 56.3% | 33.2% |
| Net Margin | 65.7% | 26.7% |
| Revenue YoY | 1808.5% | 3.2% |
| Net Profit YoY | 376.5% | 0.5% |
| EPS (diluted) | $0.25 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $19.4M | ||
| Q3 25 | $334.0K | $20.2M | ||
| Q2 25 | $1.4M | $19.1M | ||
| Q1 25 | $257.0K | $18.3M | ||
| Q4 24 | $977.0K | $18.8M | ||
| Q3 24 | $660.0K | $19.6M | ||
| Q2 24 | $736.0K | $18.6M | ||
| Q1 24 | $1.4M | $17.5M |
| Q4 25 | $12.3M | $5.2M | ||
| Q3 25 | $-8.6M | $6.2M | ||
| Q2 25 | $-6.9M | $5.1M | ||
| Q1 25 | $-5.4M | $3.6M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $-2.8M | $5.9M | ||
| Q2 24 | $-14.5M | $5.0M | ||
| Q1 24 | $411.0K | $4.3M |
| Q4 25 | 56.3% | 33.2% | ||
| Q3 25 | -2516.5% | 39.1% | ||
| Q2 25 | -701.0% | 37.1% | ||
| Q1 25 | -3350.2% | 34.3% | ||
| Q4 24 | — | 35.8% | ||
| Q3 24 | -1563.6% | 41.1% | ||
| Q2 24 | -1255.0% | 37.9% | ||
| Q1 24 | -692.5% | 35.5% |
| Q4 25 | 65.7% | 26.7% | ||
| Q3 25 | -2572.2% | 30.6% | ||
| Q2 25 | -504.8% | 26.5% | ||
| Q1 25 | -2097.7% | 19.8% | ||
| Q4 24 | — | 27.4% | ||
| Q3 24 | -425.5% | 29.9% | ||
| Q2 24 | -1964.4% | 26.8% | ||
| Q1 24 | 29.9% | 24.7% |
| Q4 25 | $0.25 | $0.36 | ||
| Q3 25 | $-0.17 | $0.43 | ||
| Q2 25 | $-0.14 | $0.35 | ||
| Q1 25 | $-0.11 | $0.25 | ||
| Q4 24 | — | $0.36 | ||
| Q3 24 | $-0.06 | $0.41 | ||
| Q2 24 | $-0.30 | $0.35 | ||
| Q1 24 | $0.01 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $1.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $49.4M | $240.3M |
| Total Assets | $59.0M | $680.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $1.0K | ||
| Q3 25 | $37.9M | $1.0K | ||
| Q2 25 | $44.8M | $1.0K | ||
| Q1 25 | $40.6M | $1.0K | ||
| Q4 24 | $59.3M | $1.0K | ||
| Q3 24 | $68.8M | $1.0K | ||
| Q2 24 | $73.0M | $1.0K | ||
| Q1 24 | $80.2M | $3.3M |
| Q4 25 | $49.4M | $240.3M | ||
| Q3 25 | $36.4M | $238.0M | ||
| Q2 25 | $44.5M | $234.6M | ||
| Q1 25 | $50.5M | $232.1M | ||
| Q4 24 | $55.1M | $231.2M | ||
| Q3 24 | $58.5M | $228.7M | ||
| Q2 24 | $60.4M | $225.4M | ||
| Q1 24 | $74.1M | $222.9M |
| Q4 25 | $59.0M | $680.9M | ||
| Q3 25 | $51.1M | $667.1M | ||
| Q2 25 | $60.7M | $653.7M | ||
| Q1 25 | $67.9M | $641.8M | ||
| Q4 24 | $90.6M | $633.5M | ||
| Q3 24 | $99.0M | $621.4M | ||
| Q2 24 | $107.8M | $610.4M | ||
| Q1 24 | $118.3M | $602.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.50× | 1.63× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $8.4M | ||
| Q3 25 | $-8.7M | $7.8M | ||
| Q2 25 | $-7.5M | $7.6M | ||
| Q1 25 | $-7.5M | $6.0M | ||
| Q4 24 | $-24.0M | $10.2M | ||
| Q3 24 | $765.0K | $7.5M | ||
| Q2 24 | $-10.9M | $6.7M | ||
| Q1 24 | $-4.0M | $6.1M |
| Q4 25 | 1.50× | 1.63× | ||
| Q3 25 | — | 1.26× | ||
| Q2 25 | — | 1.50× | ||
| Q1 25 | — | 1.65× | ||
| Q4 24 | — | 1.98× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 1.34× | ||
| Q1 24 | -9.75× | 1.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
YORW
Segment breakdown not available.
